Home › Research › Treatments
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O et al.. The journal of prevention of Alzheimer's disease, 2022-01-01
Topic: Amyloid, tau and blood-test diagnosis
Background Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. Objectives We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., et al. (2022). Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. The journal of prevention of Alzheimer's disease. https://doi.org/10.14283/jpad.2022.30
Vancouver
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. The journal of prevention of Alzheimer's disease. 2022. doi:10.14283/jpad.2022.30. PMID: 35542991.
BibTeX
@article{buddhaeberlein2022-35542991,
author = {Budd Haeberlein, S. and Aisen, P. S. and Barkhof, F. and Chalkias, S. and Chen, T. and Cohen, S. and Dent, G. and Hansson, O. and others},
title = {{Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2022},
doi = {10.14283/jpad.2022.30},
pmid = {35542991},
url = {https://doi.org/10.14283/jpad.2022.30}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
- Objectives We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease.
- Design EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early Alzheimer's disease.
- Setting These studies involved 348 sites in 20 countries.
Why it matters
EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled phase 3 trials of aducanumab, an antibody against clumped forms of amyloid beta, in people with early Alzheimer's disease, run at 348 sites in 20 countries. The authors set out to evaluate the drug's "efficacy and safety", but the text held here describes only the design and aims and reports no results, so this page cannot tell you whether aducanumab helped or what side effects it caused. Read the original paper for the findings.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants1,638
- Effect size55.2%
- Evidence strengthHigh
How this study scored 82/100
Published in a peer-reviewed journal, and it is a large phase 3 trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,638 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 7 / 7 | Cited 1,351 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 225.2 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 6 / 6 | Cited 145.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 5 / 6 | Cited by 109 other studies in this library |
| Still being cited | 4 / 4 | Cited 1,009 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Alfred W. Sandrock: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35542991) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 82 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
109 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments
Also tagged “placebo-controlled”
783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.